Skip to main content

Advertisement

Table 1 Baseline patient characteristics of patients with NHL reported to the CIBMTR from 2008 to 2014

From: Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

Variable Non-rituximab-RIC
N = 1022
Rituximab-containing RIC
N = 379
p value
Age at HCT, years    
 Median (range) 57 (18–74) 56 (28–74) 0.32
 >65 142 (14) 45 (12) 0.07
Male gender 667 (65) 248 (65) 0.95
Race    0.55
 Caucasian 918 (90) 359 (95)  
 African American 24 (2) 8 (2)  
 Others 17 (2) 10 (3)  
 Missing 63 (6) 2 (<1)  
Karnofsky performance score ≥90 622 (61) 235 (62) 0.24
HCT-CI    0.58
 0 331 (32) 141 (37)  
 1–2 301 (29) 115 (30)  
 ≥3 326 (32) 120 (32)  
 Missing 64 (6) 3 (<1)  
Histology    <0.001
 Follicular lymphoma 268 (26) 142 (37)  
 Diffuse large B cell lymphoma 452 (44) 124 (33)  
 Mantle cell lymphoma 274 (27) 106 (28)  
 Marginal zone lymphoma 28 (3) 7 (2)  
Interval from diagnosis to HCT, months    0.73
 Median (range) 36 (2-386) 39 (3-310)  
Median lines of therapy before HCT 3 (1-9) 3 (1-8) 0.54
Remission status at HCT    0.19
 Complete remission 459 (45) 147 (39)  
 Partial remission 421 (41) 169 (45)  
 Chemorefractory 125 (12) 59 (16)  
 Untreated 8 (<1) 2 (<1)  
 Unknown 9 (<1) 2 (<1)  
Disease risk index at HCT    0.003
 Low 405 (40) 184 (49)  
 Intermediate 509 (50) 151 (40)  
 High 99 (10) 42 (11)  
 Missing 9 (<1) 2 (<1)  
History of prior autologous HCT 436 (43) 99 (26) <0.001
Conditioning regimen    <0.001
 Flu/Bu ± TBI 360 (35) 21 (5)  
 Flu/Cy ± TBI 156 (15) 207 (54)  
 Flu/Mel ± TBI 271 (27) 55 (15)  
 2 Gy TBI ± Flu 196 (19) 40 (11)  
 BEAM or similar 39 (4) 56 (15)  
TBI in conditioning 265 (26) 90 (24) 0.40
ATG in conditioning 191 (19) 75 (20) 0.64
Graft source    0.02
 Bone marrow 52 (5) 8 (2)  
 Peripheral blood 970 (95) 371 (98)  
Donor type    0.10
 HLA-identical sibling 565 (55) 191 (50)  
 URD 8/8 457 (45) 188 (50)  
Donor-recipient sex match 66 (36) 227 (46) 0.62
 Male-male 434 (42) 168 (44)  
 Male-female 222 (22) 89 (23)  
 Female-male 233 (23) 80 (21)  
 Female-female 133 (13) 42 (11)  
Donor/recipient CMV status    0.14
 Both negative 305 (30) 112 (30)  
 Either donor/recipient+ 711 (70) 259 (68)  
 Missing 6 (<1) 8 (2)  
Graft-versus-host disease prophylaxis    <0.001
 Calcineurin inhibitor + MTX ± othersa
(except MMF and sirolimus)
392 (38) 207 (55)  
 Calcineurin inhibitor + MMF ± othersa
(except sirolimus)
402 (39) 95 (25)  
 Calcineurin inhibitor + sirolimus ± othersa 200 (20) 75 (20)  
 Calcineurin inhibitor alone 28 (3) 2 (<1)  
Median follow-up of survivors (range), months 37 (2–79) 47 (6–89)  
  1. Number of centers that reported only nonR-RIC cases = 76, R-RIC cases = 3, and both (nonR-RIC and R-RIC) cases = 35
  2. Abbreviations: ATG antithymocyte globulin, Bu busulfan, CMV cytomegalovirus, Cy cyclophosphamide, Flu fludarabine, HCT hematopoietic cell transplantation, HCT-CI HCT-comorbidity index, Mel melphalan, MMF mycophenolate mofetil, MTX methotrexate, TBI total body irradiation, RIC reduced-intensity conditioning
  3. aFor details, refer to Additional file 1: Table S8